SCHEMBL19735046

SCHEMBL19735046

CCc1ccc(/C=C/I)nc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.58
L3MBTL1 Q9Y468 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
HRH3 Q9Y5N1 3/20 0.37
CYP1A2 P05177 2/20 0.36
F2R P25116 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 3/20 0.33
TP53 P04637 1/20 0.33
ALDH1A1 P00352 3/20 0.32
DHFR P00374 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
CYP3A4 P08684 1/20 0.32
PKM P14618 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
NFKB1 P19838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6181463 0.84 KDM4E (0.58) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL951851 0.82 KDM4E (0.59) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL31261054 0.82 KDM4E (0.59) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL12431662 0.82 KDM4E (0.59) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL951852 0.82 KDM4E (0.59) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL13621098 0.80 KDM4E (0.58) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL662972 0.79 KDM4E (0.61) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL15007 0.79 KDM4E (0.61) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL9000467 0.78 KDM4E (0.56) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL934192 0.78 KDM4E (0.59) KDM4EL3MBTL1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362176-A1 CARBAZOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362176-A1 CARBAZOLE DERIVATIVES BTK, SYK, JAK2 KDM4E 1490/4885L3MBTL1 1355/4885SMN1; SMN2 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.